Exchange: NASDAQ
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 4/5/2013
Last 10 Quotes:
What's This?
Company Overview
Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in developing innovative therapies that target the molecular mechanisms that cause cancer.
| Name: | Onyx Pharmaceuticals Inc. |
|---|---|
| Address: | 249 East Grand Avenue South San Francisco, California 94080 |
| Phone: | (650) 266-0000 |
| Email: | NA |
| Web site: | www.onyx.com |
| CEO: | NA |
| % Owned By | Shares Bought In Last 90 Days | Shares Sold In Last 90 Days | |
| Insiders | NA | 176,908 | 123,554 |
| Institutional | 108.27% | NA | NA |
| Change in Short Interest as of 3/15/2013 | -11.31% | ||
| Short Interest as % of Float as of 3/15/2013 | 6.58% | ||
| Number of Employees | 741 |
|---|---|
| Revenue per Employee | $488,752 |
| Income per Employee | $-253,424 |
| Market Capitalization (thousands) | $6,454,620 |
| Enterprise Value (thousands) | $6,088,423 |
| Auditors Opinion | Unqualified |
Officers and Directors
N Anthony Coles, Matthew K Fust, Pablo J Cagnoni, Christopher J Kirk, Barbara Klencke, Juergen Lasowski, Helen I Torley, Antonio J Grillo-López, Corinne H Nevinny, Wendell D Wierenga, Thomas G Wiggans, Paul Goddard, Magnus Lundberg, Bill R Ringo, Randy Alan Kelley, Lori Melançon, Danielle Bertrand, John E Osborn, Julianna R Wood, Amy Figueroa, Nicole Keith, Kaye I Foster-Cheek, Suzanne M Shema, Traci McCarty
